AI-generated image
Standard Glass Lining IPO (initial public offering) will open for subscription on January 6, 2025, and close on January 8, 2025. Below is a breakdown of the engineering equipment manufacturer's strengths, weaknesses and growth prospects to help investors make an informed decision.
Standard Glass Lining IPO in a nutshell
-
Quality:
Between FY22 and FY24, Standard Glass Lining reported an average three-year
ROE and ROCE
of around 41 and 37 per cent, respectively.
-
Growth:
During FY22-24, its revenue and profit after tax grew 50 and 52 per cent annually, respectively.
-
Valuation:
At the upper price band of Rs 140, the stock is valued at a
P/E
and
P/B
ratio of around 48 and 4.3 times, respectively.
- Overview: Standard Glass Lining, which primarily makes equipment for the pharmaceutical sector, is expected to benefit from the industry's rapid growth. The pharma and chemical industries are expected to grow 9 to 11 per cent annually till 2028. India remains among the largest drug manufacturers globally, next to only China and Italy by volumes. However, stiff competition from established players remains a challenge for the company.
About Standard Glass Lining
Standard Glass Lining is an engineering equipment manufacturer that serves the pharmaceutical (82 per cent of revenue), chemical (13 per cent of revenue), and food & beverage industries. Its product portfolio includes heat transfer systems, storage tanks, pipes and fittings, glass lined solutions, vacuum pumps etc. It had a nearly 17 per cent market share in India's glass lined equipment market as of FY24. Glass lining technology is used in industries for its corrosion resistance and durability. The company has eight manufacturing facilities in Hyderabad. Its customer base included 347 companies as of September 2024.
Strengths of Standard Glass Lining
-
Solid client base:
The company counts giants like Aurobindo Pharma, Granules India, Natco Pharma, Piramal Pharma and Suven Pharmaceuticals among its clients. 13 of its top 20 customers have stayed with the company for over three years. On average, it derived close to 58 per cent of its revenue from repeat orders in the last three financial years.
- Industry-leading numbers: Standard Glass Lining tops its peers GMM Pfaudler, HLE Glascoat, Thermax and Praj Industries on annual revenue growth, EBITDA margin, ROE and ROCE for FY22-24.
Weaknesses of Standard Glass Lining
-
High working capital days:
The company had high working capital days of 151 as of FY24 as its receivables days stretched over three months. It's reliant on short-term borrowings to meet its working capital needs.
- Sectoral concentration: The company derives most of its revenue from clients in the pharma sector, which exposes it to concentration risk.
Standard Glass Lining IPO details
| Total IPO size (Rs cr) | 410 |
| Offer for sale (Rs cr) | 200 |
| Fresh issue (Rs cr) | 210 |
| Price band (Rs) | 133 - 140 |
| Subscription dates | January 6-8, 2025 |
| Purpose of issue | To fund capital expenditure, repay debt, and invest in its subsidiary |
Post-IPO
| M-cap (Rs cr) | 2,793 |
| Net worth (Rs cr) | 653 |
| Promoter holding (%) | 60.7 |
| Price-to-earnings ratio (P/E) | 47.8 |
| Price-to-book ratio (P/B) | 4.3 |
Financial history
| Key financials (Rs cr) | 2Y annual growth (%) | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Revenue | 50.5 | 544 | 498 | 240 |
| EBIT (ex OI) | 53.7 | 86 | 78 | 36 |
| PAT | 52.4 | 58 | 53 | 25 |
| Net worth | 407 | 156 | 69 | |
| Total debt | 129 | 82 | 70 | |
|
EBIT is earnings before interest and taxes (excluding other income)
PAT is profit after tax |
||||
Key ratios
| Ratios | 3Y average | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| ROE (%) | 41.1 | 20.7 | 47.6 | 54.9 |
| ROCE (%) | 37.0 | 25.5 | 43.4 | 42.0 |
| EBIT margin (%) | 15.5 | 15.7 | 15.7 | 15.1 |
| Debt-to-equity | 0.6 | 0.3 | 0.5 | 1.0 |
|
ROE is return on equity ROCE is return on capital employed |
||||
Risk report
Company and business
-
Did Standard Glass Lining report earnings before tax of Rs 50 crore or more in the last 12 months?
Yes. The company reported earnings before tax of Rs 80 crore for FY24.
-
Will the company be able to scale up its business?
Yes. The glass-lined equipment industry is projected to grow 10 per cent annually till 2028. Glass lining technology finds many applications in various industries, which should help the company scale up.
-
Does the company have recognisable brands with client stickiness?
Yes. The company has maintained long-standing relationships, spanning over three years, with 13 of its top 20 customers.
-
Does the company have a credible moat?
No. The engineering equipment market has other established players offering similar products to customers.
Management
-
Do any of the company's founders still hold at least a 5 per cent stake? Or do promoters hold over a 25 per cent stake in the company?
Yes. After the IPO, the promoters will have a 61 per cent stake in the company.
-
Do the top three managers have over 15 years of combined leadership at Standard Glass Lining?
Yes. The company's Managing Director Nageswar Rao Kandula has been with the company since its incorporation in 2012.
-
Is the management trustworthy? Is it transparent in its disclosures, which are consistent with SEBI guidelines?
Yes. There is no information to suggest otherwise.
-
Is the company's accounting policy stable?
Yes. There is no information to suggest otherwise.
-
Is Standard Glass Lining free of promoter pledging of its shares?
Yes. The promoters have not pledged their shares.
Financials
-
Did Standard Glass Lining generate a current and three-year average return on equity of more than 15 per cent and a return on capital employed of more than 18 per cent?
Yes. It has a three-year average ROE and ROCE of around 41 and 37 per cent, respectively. In FY24, it reported an ROE and ROCE of around 21 and 25 per cent, respectively.
-
Was the company's operating cash flow positive during the last three years?
No. It reported negative cash flow from operations in two of the last three years.
-
Is the company's net debt-to-equity ratio less than one?
Yes. As of September 30, 2024, the company's net debt-to-equity ratio stood at 0.3 times.
-
Is the company free from reliance on huge working capital for day-to-day affairs?
No. The company has significant working capital requirements due to its long receivable days. It takes more than three months for the company to receive payment from customers. It relies on short-term debt to meet its working capital needs.
-
Can the company run its business without relying on external funding in the next three years?
No. The company has negative operating cash flow and it's using most of the IPO proceeds to repay debt. It will likely need to raise external funds for any capex in the future.
-
Is the company free from meaningful contingent liabilities?
Yes. The company's contingent liabilities stood at 5 per cent of its net worth as of Q2 FY25.
Valuations
-
Does the stock offer an operating earnings yield of more than 8 per cent on its enterprise value?
No. The stock offers an operating earnings yield of 3 per cent on its enterprise value.
-
Is the stock's price-to-earnings less than its peers' median level?
Yes. The stock has a P/E ratio of 47.8 times compared to its peers' median level of 57.4 times.
-
Is the stock's price-to-book value less than its peers' average level?
Yes. The stock has a P/B ratio of 4.3 times compared to its peers' average level of 8.3 times.
Assessing an IPO requires a careful evaluation of a company's strengths, weaknesses, and growth potential, just like we've outlined for Standard Glass Lining. But wealth creation can only be achieved through a well-researched, balanced stock portfolio.
Our Value Research Stock Advisor can help with that. What do you get? Meticulously researched stock recommendations and ready-to-invest portfolios, updated every month. Subscribe to Value Research Stock Advisor today and take charge of your financial future.
Disclaimer: This story is not a stock recommendation. Investors should do their due diligence before investing.
Also read: Shiny profits, shady practices? Unpacking this micro-cap's spurious 52x yearly profit surge
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]






